DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 230.65

Change

0.00 (0.00)%

Market Cap

USD 0.15B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.02 (-0.06%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.01 (-0.02%)

USD 117.80B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.02 (-0.04%)

USD 92.18B
SXR8:F iShares Core S&P 500 UCITS ETF..

+0.32 (+0.06%)

USD 85.13B
FRCJ:F UBS MSCI Japan Socially Respon..

N/A

USD 75.40B
EUNL:F iShares Core MSCI World UCITS ..

-0.04 (-0.04%)

USD 72.04B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 56.70B
SXRZ:F iShares VII PLC - iShares Nikk..

-1.00 (-0.44%)

USD 55.70B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.06 (+0.06%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.03 (+0.03%)

USD 51.63B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.81% 83% B 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.81% 81% B- 66% D+
Trailing 12 Months  
Capital Gain 10.28% 54% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.28% 52% F 55% F
Trailing 5 Years  
Capital Gain 73.29% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.29% 84% B 64% D
Average Annual (5 Year Horizon)  
Capital Gain 8.67% 77% C+ 73% C
Dividend Return 8.67% 76% C+ 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.36% 67% D+ 86% B+
Risk Adjusted Return 103.68% 99% N/A 97% N/A
Market Capitalization 0.15B 35% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.